At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
Prograf vs Envarsus XR vs Astagraf XL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations
In Brief
A Phase 3 clinical trial evaluating Prograf vs Envarsus XR vs Astagraf XL and Prograf vs Astagraf XL vs Envarsus XR for Renal Failure. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus. Eligible patients will be treated with all three formulations in a pre-defined sequence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionMar 2015
TodayJul 2026
First PostedJan 15, 2015
Enrollment StartJan 1, 2015
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.5 years ago
Interventions
Prograf vs Envarsus XR vs Astagraf XLdrug
prograf vs Envarsus XR vs Astagraf XL
Prograf vs Astagraf XL vs Envarsus XRdrug
Prograf vs Astagraf XL vs Envarsus XR